Compare iShares Core S&P 500 ETF (IVV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Sanofi SA — how do they compare? iShares Core S&P 500 ETF trades at $781.9 (market cap $897.20B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: iShares Core S&P 500 ETF is far larger — about 9.4× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Sanofi SA for 94 Days on average.
| IVV | SNY | |
|---|---|---|
Market Cap | $897.20B | $95.18B |
Volume | 4,580,672 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $52.34 |
52-Week Low | $634.93 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).
The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
